Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S. commercialization of Rexulti to oversee the planned launch of a GLP-1 receptor ...

Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new ...

Latest effort for the company, whose Rexulti treats dementia, is a PBS documentary and a study of the unpaid caregiving ...

Yes. The Rexulti Savings Card can help you save money on your prescription, including copays. You may qualify for this card if you have commercial health insurance. To learn more about the Rexulti ...

Approval makes Rexulti the lone treatment approved for agitation associated with Alzheimer’s dementia. Two FDA committees ruled in April that Rexulti’s benefits outweighed risks. The FDA has ...